| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK3475-365 | 21-20 | Metastatic Castrate Resistant Prostate Cancer (mCRPC). |
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). |
DSSG Group: Genitourinary
IRONMAN: International Registry for Men with Advanced Prostate Cancer
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| IRONMAN: International Registry for Men with Advanced Prostate Cancer | CTRIAL-IE 17-30 | Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC) |
The purpose of this study is to create an international, population-based, |